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I. PROJECT DESCRIPTION, PUBLICATION MORATORIUM INFORMATION AND 
PROJECT ID   
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Precedings HMP summary page. 
 
Project ID: 46339 
 
The length of the publication moratorium is one year from the date of initial data release.  
 
This project explores the nature of the human intestinal microbiome in healthy children and 
children with recurrent abdominal pain. The overall goal is to obtain a robust knowledge base of 
the intestinal microbiome in children without evidence of pain or gastrointestinal disease and in 
those with recurrent abdominal pain (functional abdominal pain (FAP) and FAP associated with 
changes in bowel habits, i.e., irritable bowel syndrome or IBS).  Specific aims include: 1. 
Characterize the composition of the gut microbiome in healthy children by DNA sequencing. 2. 
Determine the presence of disease-specific organism signatures of variable gut microbiomes in children 
with recurrent abdominal pain.  3. Perform functional gut metagenomics by evaluation of whole 
community gene expression profiles and discovery of disease-specific pathway signatures. Multiple 
strategies have been deployed to navigate and understand the nature of the intestinal microbiome 
in childhood. These strategies included 454 pyrosequencing-based strategies to sequence 16S 
rRNA genes and understand the detailed composition of microbes in healthy and disease groups. 
Microarray-based hybridization with the PhyloChip and quantitative real-time PCR (qPCR) 
probes were applied as complementary strategies to gain an understanding of the intestinal 
microbiome from various perspectives. Data collected and analyzed during the HMP UH2 Demo 
project, from a set of healthy and IBS children (7-12 yo) may enable the identification of core 
microbiomes in children, in addition to variable components that may distinguish healthy from 
diseased pediatric states.  Twenty-two children with IBS and twenty-two healthy children were 
enrolled and analyzed in the UH2 phase of this study. The planned enrollment targets for the 
UH2/3 phases include 50 healthy children, 50 children with FAP and 50 children with IBS 
(minimum of 3 time points per child). We are currently analyzing the dataset for the presence of 
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disease-specific signatures in the human microbiome, and correlating these microbial signatures 
with pediatric health or IBS disease status in addition to IBS subtype (e.g., diarrhea-vs 
constipation-predominant). In the next phase, whole genome shotgun sequencing and 
metatranscriptomics will be performed with a subset of children in each group. This study 
explores the nature of core and variable human microbiom in pre-adolescent healthy children and 
children with IBS.  
 
II. DATA QUALITY:   
 
The only metagenomic 16S sequencing method utilized in this study was 454 pyrosequencing 
(GS FLX with Titanium chemistry) using bar-coded universal bacterial primers 27F and 534R 
(V1V3 region), and primers 357F and 936R (V3V5 region). A total of 71 samples from 44 
children were sequenced.  We monitored the data quality of 454 sequencing data and applied the 
following filtering criteria to select the reads to be included in the analyses: the reads must 
contain at least 200 nucleotides; the average Qval for each read must be at least 20; the reads 
should have an exact bar code and exact "A" primer match; the read will be cut at first 'N' or 'n'; 
and the read can have up to 4 mismatches with the "B" primer. Using these filtering criteria, 
75.7% of the 16S 454 reads were selected for analyses.   After filtering, the average read length 
was 503 nt. Total kilobases generated was 1,938,764,206 and the total number of reads was 
3,854,402.  
 
Phylochip hybridization data included redundant probes for each taxa, and internal quality 
control within each chip. 
 
III. DATA ANALYSIS AND PUBLICATION PLANS:   
 
Data analysis: 
Our research group plans to complete the comparative analyses of pediatric intestinal 
microbiomes from healthy children and children with IBS. Two primary studies are ongoing. We 
are comparing the intestinal microbiomes of healthy children (7-12 yo) with that of healthy 
adults (from the Jumpstart component of HMP). Secondly, we are comparing the intestinal 
microbiomes of healthy children with that of children with disease (IBS in this case). All 
metagenomic 16S and Phylochip data are examined using a variety of statistical algorithms in 
order to identify sources of variation in the microbiomes of healthy and IBS children.  More 
specifically, the 16S data are analyzed using both phylogenetic and OTU methods contained in 
the QIIME platform version 1.0.0 (Caporuso. Nature Methods 2010; 7: 335-6).  We employ a 
multistep OTU picking process in QIIME.  The full input dataset is first run through a fast 
method to collapse similar sequences and then a slower more robust method such as CDHIT or 
Mothur (furthest/nearest neighbors). OTU maps are merged to match final OTU IDs with Input 
Identifiers.  The QIIME platform allows us to generate a series of Phylogenetic and Non- 
phylogenetic Principal Coordinate Analyses (PCoA) plots.  Evaluating these multiple types of 
PCoA analysis will allow us to identify and confirm clustering by age group (7-9, 10-12), 
gender, status (IBS/Healthy), stool characteristics and frequency, pain quality and severity, and 
interference with daily activities. Moreover, different analyses should help us to define a core 
microbiome in healthy children and disease signatures that correlate with disease phenotypes.  
The QIIME platform also allows for flexibility in choosing a variety of taxonomies (RDP, Silva 
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(Schloss), Greengenes).  We have developed a RDP pipeline which utilizes the RDP classifier to 
generate taxa at the Phylum, Class, Order, Family and Genus level. Machine learning methods 
are being developed in order to further interrogate the 16S rRNA gene sequence data. Phylochip 
data were further analyzed to examine (dis)similarity in community composition across all 
samples. A Bray-Curtis distance matrix is generated and used to construct a non-metric 
dimensional scaling plot of communities present on the PhyloChip. Comparisons between the 
results of the PhyloChip and 454 data are also performed in order to identify taxa that are only 
identified by one technique, and could help to refine the primer design strategy for 454 DNA 
sequencing. Future studies include whole genome shotgun sequencing (Illumina GA and HiSeq) 
and metatranscriptomics (ABI SOLiD).      
Publication plan: We plan to submit the initial results of 16S metagenomic sequencing, 
PhyloChip, and qPCR results for publication. We also plan to describe different IBS subtypes 
that have been identified using different methods during 2011, before the end of the publication 
moratorium period. 
 
IV. DATA RELEASE PLAN:   
 
Data sharing plan: Data and interpretations of findings will be openly shared with the human 
microbiome research community and scientific community at-large. Consistent with any research 
program, the P.I. and collaborators will openly share and communicate about data as information 
is obtained during the study.  As members of the DACC (Data Analysis & Coordination Center) 
consortium, we are responsible for sharing data among consortium members and uploading data 
into the public databases such as dbGaP and SRA.  Findings with the outside scientific 
community will be shared by a variety of means including electronic mail communication in 
response to specific queries, voice communication with individual scientists interested in the 
findings, and oral/written/poster presentations at meetings and conferences. Abstracts 
summarizing data may be published in scientific journals, and manuscripts will be submitted to 
journals of interest. Published manuscripts will be deposited in PubMed Central, and these 
written articles will ultimately be freely available to the scientific community at-large. Data 
reports will also be shared in a more comprehensive manner by written/oral communications 
with other research groups funded via this NIH Common Fund effort, the Human Microbiome 
Project.   
 
The Baylor College of Medicine Human Genome Sequencing Center (HGSC), which will do the 
sequencing for this project, has a long history of many community outreach activities. The 
HGSC has worked with minorities, the public at large, individual research communities and now 
is deeply immersed with the community of medical geneticists and microbiologists in the Texas 
Medical Center. The HGSC uses a number of methods to convey information to the research 
communities about the various sequencing projects beyond submissions to international 
repositories.  The primary communication through the public website highlights each genome, 
including individual microbial genome projects and the HMP. Information provided includes 
descriptions of the projects, ftp sites for downloading data, available BLAST services, and links 
to related information such as mapping resources. We work with research groups using semi-
private communications such as listservs, wiki pages, access-controlled ftp sites, and annotation 
databases.  We participate in several of the DACC consortium workgroups such as the Data 
Analysis, Annotation, Metabolic Reconstruction, and Statistical Analysis Work Groups.   
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.5
22
8.
1 
: P
os
te
d 
10
 N
ov
 2
01
0
 
Sharing Model Organisms:  
 
Model organisms will not be studied or developed as part of the proposed study. Only nucleic 
acid sequences from human metagenomes and human factors associated with disease-specific 
differences in the microbiome will be explored. In the event that newly identified microbial 
genes are considered for recombinant DNA applications and creation of genetically engineered 
bacteria for therapeutic purposes, these genes and organisms will be openly shared with the 
scientific community.   
 
Genome-Wide Association Studies:  
 
This study does not include plans for genome-wide association studies.  No human genome-wide 
studies will be performed. Differences in microbial gene content or the presence of specific 
microbes may be associated with different disease phenotypes, and any such findings or 
associated data will be submitted to the NIH-designated GWAS data repository (as these 
information repositories are developed, as part of the Human Microbiome Project). 
 
The data release plan will be pursued in accordance with the policies established for the Human 
Microbiome Project and NIDDK (NIH).  Clinical data are being deposited in dbGaP, and next 
generation DNA sequence data (Roche 454, Illumina HiSeq, and ABI SOLiD) are being 
submitted to SRA. The UH2 phase data were deposited on May 25, 2010. A 12-month 
publication moratorium period has been established for this dataset.  
 
 
V. CONTACT PERSONS:  
 
James Versalovic, M.D., Ph.D., Baylor College of Medicine and Texas Children's Hospital,  
jamesv@bcm.edu 
Robert J. Shulman, M.D., Baylor College of Medicine, Children’s Nutrition Research Center, 
and Texas Children’s Hospital 
rshulman@bcm.edu 
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